Influence of cholesterol-lowering on plasma membrane lipids and function

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Cell Biology

Background:

• Hypercholesterolemia is linked to altered lipid profiles and impaired cellular function.
• Transmembrane cationic transport systems in erythrocytes and platelets are crucial for cellular homeostasis.
• The impact of cholesterol-lowering on these systems requires further investigation.

Purpose of the Study:

• To investigate the effects of HMG-CoA reductase inhibitor therapy on membrane and plasma lipids.
• To determine the impact of lipid alterations on transmembrane cationic transport in erythrocytes and platelets.
• To assess changes in cationic fluxes and intracellular concentrations during cholesterol reduction.

Main Methods:

• A 6-month double-blind, placebo-controlled study involving hypercholesterolemic patients.
• Administration of pravastatin at varying doses (10-40 mg) or placebo.
• Assays of plasma lipids, lipoproteins, apolipoproteins, membrane lipids, and cationic fluxes/concentrations in erythrocytes and platelets.

Main Results:

• Pravastatin significantly decreased plasma total cholesterol, LDL-cholesterol, and phospholipids.
• Erythrocyte and platelet membrane cholesterol content were reduced by pravastatin therapy.
• Intracellular Na+ concentration decreased, while Na+/K+ pump activity increased in erythrocytes and platelets.

Conclusions:

• Cholesterol lowering with pravastatin reduces membrane cholesterol in erythrocytes and platelets.
• These lipid changes are associated with enhanced Na+ pump activity and reduced intracellular Na+.
• Further research is needed to determine if these effects extend to other cell types.